2023年5月2日

吠檀多生物科学,临床分期的公司正在开发一个潜在的新类别的口服疗法基于定义的细菌财团——宣布它已经筹集了1.065亿美元以支持临床发展的领先候选人VE303预防复发的Clostridioides固执的感染(CDI)和一个第二阶段的研究为溃疡性结肠炎VE202,和其他开发活动。投资者财团是由新投资者共同安盛alt和AMR行动基金现有投资者比尔和梅林达•盖茨基金会,Skyviews生命科学,重塑企业,Fiscus Ventures PEAK6这和大西洋海王星。新投资者K2 HealthVentures、韩国投资伙伴、韩国投资证券亚洲有限公司和韩国投资证券,和现有的投资者包括联合创始人PureTech卫生,启示伙伴,四投资管理,Seventure伙伴,汉布罗津贴,辉瑞也出席了会议。VE303研究:VE303研究将是第一个关键阶段3的研究治疗候选人基于定义细菌财团——吠檀多是开创性的新一代微生物组治疗方法。并定义细菌细胞银行财团是标准化的成分制造的产物,绕过需要依靠捐赠粪便的组成不一致。资金将用于:收益将推进的主要使用一个关键阶段3 VE303研究复发性CDI和概念验证阶段2 VE202研究溃疡性结肠炎。和吠檀多的积极VE303第二阶段数据反复CDI最近发表在《美国医学协会杂志》(JAMA)。梭状芽孢杆菌导致大约一百万感染每年在美国,包括165000反复感染,和高达每年45000人的死亡有关。第二阶段研究的积极成果,首次报道2021年10月,这引发了一个价值2380万美元的合同选项从生物医学高级研究和发展机构(BARDA)支持VE303的3期临床研究。这个项目的部分资金就来自联邦基金的健康和人类服务; Administration for Strategic Preparedness and Response; BARDA, under contract number 75A5012C00177 for a contract value of up to $81.9 million. In conjunction with their investments, Curt LaBelle, M.D., Martin Heidecker, Ph.D., and Neil Tiwari will join Vedanta’s Board of Directors. Dr. And LaBelle has been investing in and working with healthcare companies for over 20 years and is the Managing Partner of Global Healthcare Strategies at AXA IM Alts. Dr. Heidecker brings over 20 years of extensive international experience in venture capital, drug development, and pharmaceutical marketing, and is the Chief Investment Officer of The AMR Action Fund. Tiwari brings over 15 years of healthcare experience in medical devices, pharmaceuticals, biotechnology, and health technology as an operator, investor, and board member, and is a healthcare, life sciences, and technology investor at Magnetar Capital. Plus 2 directors will conclude their tenure on Vedanta’s board, including Christopher Viehbacher, recently appointed Chief Executive Officer of Biogen, and Bharatt Chowrira, Ph.D., J.D., the President, Chief Business, Legal and Operating Officer of PureTech Health. And Charles Sherwood III, Associate General Counsel at PureTech, will replace Dr. Chowrira on the Vedanta Board of Directors. KEY QUOTES: “We are grateful to have the support of our new and existing investors, who share our vision of pioneering microbiome therapeutics based on defined bacterial consortia to transform the lives of patients with serious diseases. Our Phase 2 clinical data and this new funding enable us to continue advancing the microbiome field beyond products made from fecal donations, and towards pharmaceutical-grade, defined medicines.” — Bernat Olle, Ph.D., Co-founder and Chief Executive Officer of Vedanta Biosciences “We extend our warm thanks to Chris and Bharatt for their several years of expert guidance and contributions to advancing our mission, and welcome our new Board members.” — Dr. Olle